Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance.

摘要: Abstract Background: Despite the availability of a growing number potent antiretroviral agents, efforts to completely suppress viral replication in patients with HIV-1 infection are limited because increasing risk resistance. Tipranavir (TPV) is first class agents known as nonpeptidic protease inhibitors (PIs). TPV exhibits resistance profile distinct from that other currently available PIs, making it potential option for treatment experienced multiple Pls. Objective: This article discusses clinical pharmacology and efficacy who highly or harbor PI-resistant virus. Methods: A search was conducted English language, peer-reviewed articles abstracts indexed on MEDLINE Current Contents databases (1966-May 2007) using terms tipranavir, Aptivus, inhibitor, human immunodeficiency virus, . Product information national international AIDS retrovirus meetings (2005-2006) were also reviewed. Results: Use combination ritonavir (TPV/r) approved by US Food Drug Administration based 2 Phase III studies. In these studies, HIV-infected extensive experience including nucleoside analogues, nonnucleoside reverse transcriptase inhibitors, randomized receive TPV/r ritonavir-boosted comparator PI. All had evidence PIs. The specific (amprenavir, indinavir, lopinavir, saquinavir) selected each patient aid testing. Each received an optimized background regimen which could include enfuvirtide. At 24, 48, 96 weeks, group higher rates virologic response (defined ≥1 log10 decrease HIV RNA) suppression (to Conclusions: Although has mechanism action similar earlier-generation activity against strains Currently, indicated use PI